Publicité
La bourse ferme dans 23 min

  • CAC 40

    8 096,36
    +79,71 (+0,99 %)
     

  • Euro Stoxx 50

    5 007,01
    +68,00 (+1,38 %)
     

  • Dow Jones

    38 213,04
    +127,24 (+0,33 %)
     

  • EUR/USD

    1,0684
    -0,0049 (-0,46 %)
     

  • Gold future

    2 344,80
    +2,30 (+0,10 %)
     

  • Bitcoin EUR

    59 731,66
    +511,32 (+0,86 %)
     

  • CMC Crypto 200

    1 330,34
    -66,20 (-4,74 %)
     

  • Pétrole WTI

    83,68
    +0,11 (+0,13 %)
     

  • DAX

    18 157,92
    +240,64 (+1,34 %)
     

  • FTSE 100

    8 137,90
    +59,04 (+0,73 %)
     

  • Nasdaq

    15 948,53
    +336,77 (+2,16 %)
     

  • S&P 500

    5 105,26
    +56,84 (+1,13 %)
     

  • Nikkei 225

    37 934,76
    +306,28 (+0,81 %)
     

  • HANG SENG

    17 651,15
    +366,61 (+2,12 %)
     

  • GBP/USD

    1,2462
    -0,0049 (-0,39 %)
     

Huntington’s Disease - Competitive Landscape in 2021

ReportLinker
·2 min de lecture

Summary "Huntington’s Disease - Competitive Landscape in 2021" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

New York, March 12, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Huntington’s Disease - Competitive Landscape in 2021" - https://www.reportlinker.com/p06035017/?utm_source=GNW


Huntington’s disease (HD) protein is a major target of drug developers.There are 138 drugs in the pipeline, 99% 0f which are in early-stage.

Mid-sized Pharma companies dominates R&D in this indication. The addition of improved asymptomatic treatments and potential disease-modifying drugs for HD is expected to drive market growth.

This reports provides a data-driven overview of the current and future competitive landscape in HD therapeutics.

Scope
Components of the report include -
- Disease epidemiology
- Marketed drugs assessment
- Pipeline drugs assessment
- Clinical trials assessment
- Commercial assessment
- Social media overview
- Digital marketing overview

Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HD in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Read the full report: https://www.reportlinker.com/p06035017/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001